Patents by Inventor Zilun Hu

Zilun Hu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MACROCYCLES AS FACTOR XIA INHIBITORS
    Publication number: 20230058729
    Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein all the variables are as defined herein. These compounds are selective Factor XIa inhibitors or dual inhibitors of fXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
    Type: Application
    Filed: October 4, 2021
    Publication date: February 23, 2023
    Inventors: James R. CORTE, Tianan FANG, Carl P. DECICCO, Donald J.P. PINTO, Karen A. ROSSI, Zilun HU, Yoon JEON, Mimi L. QUAN, Joanne M. SMALLHEER, Yufeng WANG, Wu YANG
  • Macrocycles as factor XIA inhibitors
    Patent number: 11136327
    Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein all the variables are as defined herein. These compounds are selective Factor XIa inhibitors or dual inhibitors of fXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
    Type: Grant
    Filed: November 21, 2019
    Date of Patent: October 5, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventors: James R. Corte, Tianan Fang, Carl P. Decicco, Donald J. P. Pinto, Karen A. Rossi, Zilun Hu, Yoon Jeon, Mimi L. Quan, Joanne M. Smallheer, Yufeng Wang, Wu Yang
  • Lactam, cyclic urea and carbamate, and triazolone derivatives as potent and selective rock inhibitors
    Patent number: 10730858
    Abstract: The present invention provides compounds of Formula (I): Formula (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.
    Type: Grant
    Filed: July 6, 2017
    Date of Patent: August 4, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: Zilun Hu, Cailan Wang, Mimi L. Quan, Peter W. Glunz
  • MACROCYCLES AS FACTOR XIA INHIBITORS
    Publication number: 20200087312
    Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein all the variables are as defined herein. These compounds are selective Factor XIa inhibitors or dual inhibitors of fXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
    Type: Application
    Filed: November 21, 2019
    Publication date: March 19, 2020
    Inventors: James R. Corte, Tianan Fang, Carl P. Decicco, Donald J.P. Pinto, Karen A. Rossi, Zilun Hu, Yoon Jeon, Mimi L. Quan, Joanne M. Smallheer, Yufeng Wang, Wu Yang
  • Macrocycles as factor XIa inhibitors
    Patent number: 10487086
    Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein all the variables are as defined herein. These compounds are selective Factor XIa inhibitors or dual inhibitors of fXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
    Type: Grant
    Filed: September 28, 2017
    Date of Patent: November 26, 2019
    Assignee: Bristol-Myers Squibb Company
    Inventors: James R. Corte, Tianan Fang, Carl P. Decicco, Donald J. P. Pinto, Karen A. Rossi, Zilun Hu, Yoon Jeon, Mimi L. Quan, Joanne M. Smallheer, Yufeng Wang, Wu Yang
  • LACTAM, CYCLIC UREA AND CARBAMATE, AND TRIAZOLONE DERIVATIVES AS POTENT AND SELECTIVE ROCK INHIBITORS
    Publication number: 20190300510
    Abstract: The present invention provides compounds of Formula (I): Formula (I) or reoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.
    Type: Application
    Filed: July 6, 2017
    Publication date: October 3, 2019
    Inventors: Zilun Hu, Cailan Wang, Mimi L. Quan, Peter W. Glunz
  • Tied-back benzamide derivatives as potent rock inhibitors
    Patent number: 10112939
    Abstract: The present invention provides compounds of Formula (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.
    Type: Grant
    Filed: August 20, 2015
    Date of Patent: October 30, 2018
    Assignee: Bristol-Myers Squibb Company
    Inventors: Zilun Hu, Doree F. Sitkoff, Mimi L. Quan
  • Diamide macrocycles that are FXIa inhibitors
    Patent number: 10081623
    Abstract: The present invention provides compounds of Formula (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective Factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
    Type: Grant
    Filed: September 3, 2015
    Date of Patent: September 25, 2018
    Assignee: Bristol-Myers Squibb Company
    Inventors: Jun Shi, William R. Ewing, Laura Nielsen, Zilun Hu, Mimi L. Quan
  • SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK
    Publication number: 20180155296
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically-acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.
    Type: Application
    Filed: February 1, 2018
    Publication date: June 7, 2018
    Inventors: Vladimir Ladziata, Peter W. Glunz, Zilun Hu, Yufeng Wang
  • Tricyclic pyrido-carboxamide derivatives as rock inhibitors
    Patent number: 9914740
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.
    Type: Grant
    Filed: July 1, 2014
    Date of Patent: March 13, 2018
    Assignee: Bristol-Myers Squibb Company
    Inventors: Mimi L. Quan, Zilun Hu, Cailan Wang, Sharanabasappa Patil
  • Spirocycloheptanes as inhibitors of rock
    Patent number: 9902702
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically-acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.
    Type: Grant
    Filed: July 13, 2015
    Date of Patent: February 27, 2018
    Assignee: Bristol-Myers Squibb Company
    Inventors: Vladimir Ladziata, Peter W. Glunz, Zilun Hu, Yufeng Wang
  • MACROCYCLES AS FACTOR XIA INHIBITORS
    Publication number: 20180022753
    Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein all the variables are as defined herein. These compounds are selective Factor XIa inhibitors or dual inhibitors of fXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
    Type: Application
    Filed: September 28, 2017
    Publication date: January 25, 2018
    Inventors: James R. Corte, Tianan Fang, Carl P. Decicco, Donald J.P. Pinto, Karen A. Rossi, Zilun Hu, Yoon Jeon, Mimi L. Quan, Joanne M. Smallheer, Yufeng Wang, Wu Yang
  • Phenylpyrazole derivatives as potent ROCK1 and ROCK2 inhibitors
    Patent number: 9828345
    Abstract: The present invention provides compounds of Formula (I): (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.
    Type: Grant
    Filed: February 28, 2014
    Date of Patent: November 28, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Zilun Hu, Mimi L. Quan
  • Macrocycles as factor XIa inhibitors
    Patent number: 9802939
    Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein all the variables are as defined herein. These compounds are selective Factor XIa inhibitors or dual inhibitors of fXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
    Type: Grant
    Filed: December 22, 2014
    Date of Patent: October 31, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: James R. Corte, Tianan Fang, Carl P. Decicco, Donald J. P. Pinto, Karen A. Rossi, Zilun Hu, Yoon Jeon, Mimi L. Quan, Joanne M. Smallheer, Yufeng Wang, Wu Yang
  • DIAMIDE MACROCYCLES THAT ARE FXIA INHIBITORS
    Publication number: 20170283403
    Abstract: The present invention provides compounds of Formula (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective Factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
    Type: Application
    Filed: September 3, 2015
    Publication date: October 5, 2017
    Inventors: Jun Shi, William R. Ewing, Laura Nielsen, Zilun HU, Mimi L. Quan
  • TIED-BACK BENZAMIDE DERIVATIVES AS POTENT ROCK INHIBITORS
    Publication number: 20170226105
    Abstract: The present invention provides compounds of Formula (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.
    Type: Application
    Filed: August 20, 2015
    Publication date: August 10, 2017
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Zilun Hu, Doree F. Sitkoff, Mimi L. Quan
  • Tricyclic pyrido-carboxamide derivatives as rock inhibitors
    Patent number: 9663529
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.
    Type: Grant
    Filed: July 1, 2014
    Date of Patent: May 30, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Mimi L. Quan, Zilun Hu, Cailan Wang
  • Phenylpyrazole derivatives as potent ROCK1 and ROCK2 inhibitors
    Patent number: 9458110
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.
    Type: Grant
    Filed: February 28, 2014
    Date of Patent: October 4, 2016
    Assignee: Bristol-Myers Squibb Company
    Inventors: Mimi L. Quan, Zilun Hu, Cailan Wang, Peter W. Glunz
  • TRICYCLIC PYRIDO-CARBOXAMIDE DERIVATIVES AS ROCK INHIBITORS
    Publication number: 20160152627
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.
    Type: Application
    Filed: July 1, 2014
    Publication date: June 2, 2016
    Inventors: Mimi L. Quan, Zilun Hu, Cailan Wang
  • TRICYCLIC PYRIDO-CARBOXAMIDE DERIVATIVES AS ROCK INHIBITORS
    Publication number: 20160152628
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.
    Type: Application
    Filed: July 1, 2014
    Publication date: June 2, 2016
    Inventors: Mimi L. Quan, Zilun Hu, Cailan Wang, Sharanabasappa Patil